Pulmonology

Doç. Dr. Nuran Katgı

Doctor and researcher Medicana International İzmir İzmir
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

CV

Education and experience

From source

Experience

  • 2003-2009İzmir Dr. Suat Seren Göğüs Hastalıkları ve Cerrahisi Eğitim ve Araştırma Hastanesi – Göğüs Hastalıkları Asistanımedicana.com.tr
  • 2009-2024İzmir Dr. Suat Seren Göğüs Hastalıkları ve Cerrahisi Eğitim ve Araştırma Hastanesi – Göğüs Hastalıkları Uzmanımedicana.com.tr
  • 2024-2025İzmir Dr. Suat Seren Göğüs Hastalıkları ve Cerrahisi Eğitim ve Araştırma Hastanesi – Göğüs Hastalıkları Doçentimedicana.com.tr

Education

  • 1999Dicle Üniversitesi Tıp Fakültesimedicana.com.tr
  • 2009İzmir Dr. Suat Seren Göğüs Hastalıkları ve Cerrahisi Eğitim ve Araştırma Hastanesimedicana.com.tr

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyPulmonologymedicana.com.trFrom source
  • InstitutionMedicana International İzmirmedicana.com.trFrom source
  • Publications13 publicationsmedicana.com.tr profile pageFrom source
  • Last synchronised7 November 2026 03:24https://www.medicana.com.tr/hekim-detay/23487/nuran-katgimedicana.com.tr

Scientific work

Publications

13 publications

  1. Toplumdan Kökenli Pnömoni Nedeniyle Hastanede Yatan Yaşlı Hastaların (> 65 Yaş) Özellikleri ve Ekonomik Yükü – Abant Medical Journal, 2022; Katgı N., Çimen P., Ayrancı A., Tuksavul F.F.

    Source: medicana.com.tr profile page

  2. Telisotuzumab Vedotin Monotherapy in Previously Treated c-MET–Overexpressing Non-Squamous EGFR Wild-Type Advanced NSCLC: LUMINOSITY Trial – Updated Analysis – Journal of Thoracic Oncology, 2025; Katgı N. ve ark.

    Source: medicana.com.tr profile page

  3. Telisotuzumab Vedotin Monotherapy in NSCLC: Primary Analysis of LUMINOSITY Trial – Journal of Clinical Oncology, 2024; Katgı N. ve ark.

    Source: medicana.com.tr profile page

  4. Efficiency and Reliability of Bronchoscopic Lung Volume Reduction Coil Application in Severe Emphysema – 2024; Katgı N. ve ark.

    Source: medicana.com.tr profile page

  5. Comparison of Alectinib and Crizotinib in ALK Positive Advanced NSCLC: Real-Life Data – Thoracic Research and Practice, 2023; Katgı N. ve ark.

    Source: medicana.com.tr profile page

  6. Relationship Between Thyroid Transcription Factor 1 (TTF 1) Positivity and EGFR Mutation in Lung Adenocarcinoma – Eurasian Journal of Pulmonology, 2023; Katgı N. ve ark.

    Source: medicana.com.tr profile page

  7. COVID-19 Hastalarında Prognostik Faktörler ve Eozinofillerin Rolü – Journal of İzmir Chest Hospital, 2023; Katgı N. ve ark.

    Source: medicana.com.tr profile page

  8. Prediction of EGFR and ALK Mutations by 18F FDG PET/CT Texture Analysis in Lung Adenocarcinoma – Nüklearmedizin, 2022; Katgı N. ve ark.

    Source: medicana.com.tr profile page

  9. Prognostic Value of 18F FDG PET/CT Metabolic Parameters in Advanced Lung Adenocarcinoma – Molecular Imaging and Radionuclide Therapy, 2022; Katgı N. ve ark.

    Source: medicana.com.tr profile page

  10. Real-Life Comparison of Afatinib vs Erlotinib in Rare EGFR Exon 18/20 Mutations: TOG Study – Journal of Cancer Research and Clinical Oncology, 2022; Katgı N. ve ark.

    Source: medicana.com.tr profile page

View all 13 publications